Search

Displaying results 2181 - 2190 of 10000 in total
  1. Target

    Copper-transporting ATPase 2

    go.drugbank.com/bio_entities/BE0003664
    TransporterHumans

    Copper ion transmembrane transporter involved in the export of copper out of the cells. … It is involved in copper homeostasis in the liver, where it ensures the efflux of copper from hepatocytes into the bile in response to copper overload

    Polypeptides: Copper-transporting ATPase 2Synonyms: Copper pump 2
  2. Target

    CMV DNA Terminase Complex

    go.drugbank.com/bio_entities/BE0010221
    TargetHuman Cytomegalovirus

    Forms a tripartite terminase complex together with TRM2 and TRM3 in the host cytoplasm. Once the complex reaches the host nucleus, it interacts with the capsid portal vertex. … Forms a tripartite terminase complex together with TRM1 and TRM3 in the host cytoplasm. Once the complex reaches the host nucleus, it interacts with the capsid portal vertex.

  3. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722]

  4. Drug

    Cefiderocol

    go.drugbank.com/drugs/DB14879
    ApprovedInvestigational

    [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available. … [A189150] A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … by the European Commission on December 19, 2022.

  6. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. … [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]

  7. Drug

    Clove oil

    go.drugbank.com/drugs/DB11338
    ApprovedNutraceutical

    Clove is native of Indonesia but is now cultured in several parts of the world, including Brazil in the state of _Bahia_. … Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities.

    Mixtures: DİŞİNOL 2 G + 0,5 G + 3,5 G/10 ML ÇÖZELTİCategories: Complex Mixtures
  8. Drug

    Benmoxin

    go.drugbank.com/drugs/DB09246
    ApprovedWithdrawn

    Benmoxin is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine class. It was first synthesized in 1967 and rapidly used in Europe as an antidepressant.

  9. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose … in mice) studies.

  10. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] Maralixibat represents the first FDA-approved treatment for cholestatic pruritus in patients with Alagille syndrome. It was granted FDA approval on 29 September 2021.